Home > Protocol Summaries: Compounds > fluticasone propionate

Protocol Summaries: fluticasone propionate

Protocol Summaries for fluticasone propionate
GSK
Study ID		 Phase Title Status
110341 Phase 4 A randomised, double blind, placebo controlled, 4 period, incomplete block, crossover study to assess the dose-response curve of intranasal fluticasone propionate (25, 50, 100 and 200 μg, once daily for 8 days) in the Vienna Challenge Chamber for the purpose of investigating the sensitivity Completed
111116 Phase 4 Prevalence of Chronic Airway Obstruction in Subjects with a History of Cigarette Smoking in a Primary Care Setting Completed
111983 Fluticasone propionate nasal spray (Flixonase) safety in patients with allergic rhinitis registered in the UK General Practice Research Database Active, not recruiting
ADC109043 Phase 4 An evaluation of the prevalence of airway obstruction consistent with chronic obstructive pulmonary disease (COPD) in subjects with a history of cigarette smoking and symptoms of chronic bronchitis in a primary care setting Completed
FAS106533 Phase 1 See Detailed Description Completed
FMS40273 A study to investigate the effect of inhaled fluticasone propionate on the bronchial responsiveness to leukotriene D4 in asthmatics patients Completed
HH3104994 Phase 2 A randomised, double blind, placebo controlled, 2-way crossover, 3 phase study, to investigate the trial models, Vienna Challenge Chamber, in and out of season, and Park Study in season and the clinical efficacy of rpt doses of fluticasone propionate in subjects with seasonal allergic rhinitis Completed
SCO100646 Phase 3 See Detailed Description Completed
SCO100648 Phase 3 Clinical Evaluation of GW815SF for Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema) “ A Long-term Treatment Study of GW815SF50/500µg in Chronic Obstructive Pulmonary Disease - Completed
SIG103337 Phase 2 See Detailed Description Completed

Filter list by: